Drug Profile
Research programme: antioxidant response element activators - Roche
Alternative Names: ARE activators; Keap1-Nrf2 pathway modulatorsLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator InterMune
- Developer Roche
- Class Peptides; Small molecules
- Mechanism of Action Antioxidants; NF E2 related factor 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Fibrosis in USA
- 01 May 2014 Early research in Fibrosis in USA (unspecified route)